Tag
Healthcare Diagnostics
5 articles
Thyrocare's strong Q2 FY27 results, marked by a 25.1% revenue increase and 25.7% profit growth, highlight the continued momentum within the Indian diagnostics sector. The divestment of its NHL subsidiary, while resulting in a one-time impairment charge, signals a strategic refocus on core franchise and institutional partnerships, alongside expansion into specialty diagnostics like allergy and genomics testing. With 61.6 million tests processed and the addition of new laboratories and franchisees, Thyrocare is reinforcing its operational capabilities and market reach, positioning the company for sustained growth despite potential headwinds from margin pressures and competitive dynamics. Investors should watch for the successful execution of the company’s growth strategy and its ability to maintain quality standards amidst expanding operations.
Star Imaging H1 FY27 Revenue Up 8% YoY
Star Imaging reported H1 FY27 revenue of ₹48.9 crore, an 8% YoY increase, with B2B and B2C segments growing 20% and 21% respectively.
EBITDA margin moderated to 28.9% due to upfront growth investments
Lord's Mark Industries H1 FY27 Investor Presentation
Lord's Mark Industries presents H1 FY26-27 performance, highlighting a ₹3,000+ Cr renewable energy order pipeline and expansion into MedTech.
The company forecasts 3.6x revenue growth to ₹2,586 Cr by
Star Imaging H1 FY27 Revenue Up 8% to ₹48.9 Crore
Star Imaging disclosed H1 FY27 earnings with 8% YoY revenue growth to ₹48.9 crore, though EBITDA margin contracted by 936 bps to 28.9%.
The company expanded its B2B hospital network to 150+ tie-ups an
Thyrocare Promoter Docon Sells 9.9% Stake
Promoter Docon Technologies sold 1.58 crore Thyrocare shares representing 9.9% equity via market trades on August 13, 2026.
Post-sale, promoter shareholding reduced from 60.92% to 51.02% of total paid
Thyrocare Promoter Releases Pledge on 17.5M Shares
Docon Technologies, Thyrocare's promoter, released pledge on 1.75 crore equity shares (10.99% stake) held as security for API Holdings' NCDs.
The pledge release on August 11, 2026, reduces Docon's enc